Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 5Gynecologic 4Breast 2Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 535Uterine Cervical Neoplasms 249Fallopian Tube Neoplasms 239Endometrial Neoplasms 142Carcinoma, Ovarian Epithelial 135Breast Neoplasms 101Neoplasms 74Carcinoma, Non-Small-Cell Lung 70Colorectal Neoplasms 53Uterine Cervical Dysplasia 49Papillomavirus Infections 49Neoplasm Metastasis 48Pancreatic Neoplasms 46Melanoma 44Uterine Neoplasms 43Prostatic Neoplasms 41Urinary Bladder Neoplasms 40Lung Neoplasms 40Stomach Neoplasms 38Peritoneal Neoplasms 37Recurrence 36Carcinoma, Renal Cell 35Triple Negative Breast Neoplasms 33Head and Neck Neoplasms 32Esophageal Neoplasms 31Small Cell Lung Carcinoma 30Sarcoma 28Vulvar Neoplasms 26Vaginal Neoplasms 24Testicular Neoplasms 22

Interventions

olaparib 3talazoparib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Fanconi Anemia, Complementation Group D1 × Gynecologic × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

AstraZeneca

Phase 2 Completed
97 enrolled 22 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT00494442 2018-08-01

ICEBERG 2

AstraZeneca

Phase 2 Completed
58 enrolled 13 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡